Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose

Journal of the American Society of Nephrology

Volumn 25, Issue 4, 2014, Pages 819-826

  Derebail, Vimal K ^a   Lacson, Eduardo K ^b   Kshirsagar, Abhijit V ^a   Key, Nigel S ^a   Hogan, Susan L ^a   Hakim, Raymond M ^b,c   Mooney, Ann ^b   Jani, Chinu M ^d   Johnson, Curtis ^d   Hu, Yichun ^a   Falk, Ronald J ^a   Lazarus, J Michael ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Spectra Physics Lasers Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN C; TRANSFERRIN;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CROSS-SECTIONAL STUDY; DRUG MEGADOSE; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RENAL REPLACEMENT THERAPY; SICKLE CELL TRAIT; TREATMENT OUTCOME; UNITED STATES; AGED; BLOOD; ETHNOLOGY; GENETICS; MULTIVARIATE ANALYSIS;

ADULT; AFRICAN AMERICANS; AGED; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RENAL DIALYSIS; SICKLE CELL TRAIT;

EID: 84924231078     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/asn.2013060575     Document Type: Article

References (44)

1. Schneider RG, Hightower B, Hosty TS, Ryder H, Tomlin G, Atkins R, Brimhall B, Jones RT: Abnormal hemoglobins in a quarter million people. Blood 48: 629-637, 1976
2. Heller P, Best WR, Nelson RB, Becktel J: Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Engl J Med 300: 1001-1005, 1979
3. Tsaras G, Owusu-Ansah A, Boateng FO, Amoateng-Adjepong Y: Complications associated with sickle cell trait: A brief narrative review. Am J Med 122: 507-512, 2009
4. Mitchell BL: Sickle cell trait and sudden death-bringing it home. J Natl Med Assoc 99: 300-305, 2007
5. Ataga KI, Orringer EP: Renal abnormalities in sickle cell disease. Am J Hematol 63: 205-211, 2000
6. Scheinman JI: Sicklecell disease and the kidney. Nat Clin Pract Nephrol 5: 78-88, 2009
7. Key NS, Derebail VK: Sickle-cell trait: Novel clinical significance. Hematology (Am Soc Hematol Educ Program) 2010: 418-422, 2010
8. Sesso R, Almeida MA, Figueiredo MS, Bordin JO: Renal dysfunction in patients with sickle cell anemia or sickle cell trait. Braz J Med Biol Res 31: 1257-1262, 1998
9. Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Kshirsagar AV: High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol 21: 413-417, 2010
10. Yium J, Gabow P, Johnson A, Kimberling W, Martinez-Maldonado M: Autosomal dominant polycystic kidney disease in blacks: Clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol 4: 1670-1674, 1994
11. Ajayi AA, Kolawole BA: Sickle cell trait and gender influence type 2 diabetic complications in African patients. Eur J Intern Med 15: 312-315, 2004
12. Pavone B, Bucci S, Sirolli V, Merlini G, Del Boccio P, Di Rienzo M, Felaco P, Amoroso L, Sacchetta P, Di Ilio C, Federici G, Urbani A, Bonomini M: Beta2-microglobulin causes abnormal phosphatidylserine exposure in human red blood cells. Mol Biosyst 7: 651-658, 2011
13. Lacson E Jr., Rogus J, Teng M, Lazarus JM, Hakim RM: The association ofrace with erythropoietin dose in patients on long-term hemodialysis. Am J Kidney Dis 52:1104-1114, 2008
14. Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Rosamond WD, Kshirsagar AV: Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. Kidney Int 80: 992-999, 2011
15. Petrakis NL, Wiesenfeld SL, Sams BJ, Collen MF, Cutler JL, Siegelaub AB: Prevalence of sickle-cell trait and glucose-6-phosphate de-hydrogenase deficiency. N Engl J Med 282: 767-770, 1970
16. Janerich DT, Kelly JH, Ziegler FD, Selvin S, Porter IH, Robinson JB, Herdman RC: Agetrends in the prevalence of the sickle cell trait. Health Serv Rep 88: 804-807, 1973
17. Hicks EJ, Miller GD, Horton R: Prevalence of sickle cell trait and HbC-trait in Blacks from low socioeconomic conditions. Am J Public Health 68: 1135-1137, 1978
18. Hicks PJ, Langefeld CD, Lu L, Bleyer AJ, Divers J, Nachman PH, Derebail VK, Bowden DW, Freedman BI: Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans. Kidney Int 80: 1339-1343, 2011
19. Cavanaugh KL, Lanzkron S: Time to recognize an overlooked trait. J Am Soc Nephrol 21: 385-386, 2010
20. Martin TW, Weisman IM, Zeballos RJ, Stephenson SR: Exercise and hypoxia increase sickling in venous blood from an exercising limb in individuals with sickle cell trait. Am J Med 87: 48-56, 1989
21. Connes P, Hue O, Tripette J, Hardy-Dessources MD: Blood rheology abnormalities and vascular cell adhesion mechanisms in sickle cell trait carriers during exercise. Clin Hemorheol Microcirc 39: 179-184, 2008
22. Hingorani M, BentleyCR, Jackson H, Betancourt F, Arya R, Aclimandos WA, Bird AC: Retinopathy in haemoglobin C trait. Eye (Lond) 10: 338-342, 1996
23. Bergeron MF, Cannon JG, Hall EL, Kutlar A: Erythrocyte sickling during exercise and thermal stress. Clin J Sport Med 14: 354-356, 2004
24. Gibson BR, Peterson AC, Costabile RA: Priapism associated with hemoglobin C trait. J Urol 168: 2122, 2002
25. Brittain J, Derebail VK, Mooberry MJ, Ataga KI, Kshirsagar AV, Key NS: Increased red cell phosphatidylserine exposure correlates with enhanced thrombin generation in sickle cell trait patients with end-stage renal disease [Abstract]. Blood 116: 2665, 2010
26. Voulgari PV, Chaidos A, Tzouvara E, Alymara V, Alamanos Y, Drosos AA, Bourantas KL: Antierythropoietin antibodies in thalassemia patients. Ann Hematol 83: 22-27, 2004
27. Hedo CC, Aken'ova YA, Okpala IE, Durojaiye AO, Salimonu LS: Acute phase reactants and severity of homozygous sickle cell disease. J Intern Med 233: 467-470, 1993
28. Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A: Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol 61: 49-54, 1998
29. Stenvinkel P: The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 16[Suppl 7]: 36-40, 2001
30. Adamson JW: Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: The many faces of inflammation. Adv Chronic Kidney Dis 16: 76-82, 2009
31. Kwack C, Balakrishnan VS: Managing erythropoietin hyporesponsiveness. Semin Dial 19: 146-151, 2006
32. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocritvalues in patients with cardiacdisease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
33. DrùekeTB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
34. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
35. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
36. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
37. Centers for Medicare & Medicaid Services (CMS)HHS: Medicare program; end-stage renal disease prospective payment system. Final rule. Fed Regist 75: 49029-49214, 2010
38. Charytan C: Bundled-rate legislation for Medicare reimbursement for dialysis services: Implications foranemia management with ESAs. Clin J Am Soc Nephrol 5: 2355-2362, 2010
39. Roach JL, Turenne MN, Hirth RA, Wheeler JR, Sleeman KS, Messana JM: Using race as a case-mix adjustment factor in a renal dialysis payment system: Potential and pitfalls. Am J Kidney Dis 56: 928-936, 2010
40. Thomson Reuters (Healthcare): RedBook2010(RedBookDrug Topics) (Red Book: Pharmacy's Fundamental Reference), Montvale, NJ: PDR Network, LLC, 2010
41. US Renal Data System: USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012
42. Krishnan M, Wilfehrt HM, Lacson E Jr.: In data we trust: The role and utility of dialysis providerdatabases in the policy process. Clin J Am Soc Nephrol 7: 1891-1896, 2012
43. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP: Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis53: 823834, 2009
44. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE: Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models, New York, Springer, 2012